Elicio Therapeutics (ELTX) just unveiled an update.
Elicio Therapeutics, Inc. has shared encouraging preliminary results from the AMPLIFY-7P Phase 1a study of their experimental cancer vaccine, ELI-002 7P, which targets mKRAS-driven solid tumors. The data, as of May 2024, reveal that patients receiving a higher dose of the vaccine have not yet reached the median disease-free survival endpoint, indicating potential effectiveness. Those with higher T cell responses to the vaccine also showed no signs of disease progression, highlighting the promise of ELI-002 7P in treating such challenging cancers.
See more insights into ELTX stock on TipRanks’ Stock Analysis page.
